FLT3 and acute myeloid leukemia: Bregante et al. identified 2 out of 18 compounds active against FLT3-ITD AML, WS6 and Ispinesib, and combined them with two approved drugs, Ponatinib and Cabozantinib, in in vitro models (AML cell lines and samples) [73].